Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jiping Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7466-098X; OpenAlex author ID A5100679498. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 8

  1. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  2. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  3. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma. Last author DOI 10.1001/jamaoncol.2021.5407↗
  4. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  5. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  6. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-020-08717-x↗
  7. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-019-08087-z↗
  8. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer-Standard of Care or Still Worth Debating? First author DOI 10.1245/s10434-019-08135-8↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 6 shared papers, 2020–2024 · strength 0.78
  2. Thomas E. Clancy · 6 shared papers, 2020–2024 · strength 0.76
  3. Joseph Douglas Mancias · 4 shared papers, 2020–2024 · strength 0.50
  4. Andressa Dias Costa · 4 shared papers, 2021–2024 · strength 0.47
  5. Jonathan Andrew Nowak · 4 shared papers, 2021–2024 · strength 0.47
  6. Akhil Chawla · 3 shared papers, 2020–2022 · strength 0.46
  7. David C. Linehan · 3 shared papers, 2021–2023 · strength 0.31
  8. Albert C. Koong · 3 shared papers, 2021–2023 · strength 0.31
  9. Chen Yuan · 3 shared papers, 2021–2023 · strength 0.31
  10. Richard Francis Dunne · 3 shared papers, 2021–2023 · strength 0.31
  11. Douglas Adam Rubinson · 3 shared papers, 2021–2023 · strength 0.31
  12. Vicente Morales‐Oyarvide · 3 shared papers, 2021–2023 · strength 0.31
  13. Hannah L. Williams · 3 shared papers, 2021–2023 · strength 0.31
  14. Margaret M. Kozak · 3 shared papers, 2021–2023 · strength 0.31
  15. Sara A. Väyrynen · 3 shared papers, 2021–2023 · strength 0.31
  16. Daniel Tandel Chang · 3 shared papers, 2021–2023 · strength 0.31
  17. Aram F. Hezel · 3 shared papers, 2021–2023 · strength 0.31
  18. Andrew J. Aguirre · 3 shared papers, 2021–2023 · strength 0.31
  19. George Molina · 2 shared papers, 2020–2021 · strength 0.29
  20. Stephanie K. Dougan · 2 shared papers, 2022–2024 · strength 0.27
  21. Osama E. Rahma · 2 shared papers, 2021–2024 · strength 0.25
  22. Harshabad Singh · 2 shared papers, 2022–2023 · strength 0.22
  23. Kimberly J. Perez · 2 shared papers, 2022–2023 · strength 0.22
  24. James M. Cleary · 2 shared papers, 2022–2023 · strength 0.22
  25. Winta Tsegay Mehtsun · 1 shared paper, 2022 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.